Strongbridge Biopharma (NASDAQ:SBBP) reported topline data from its Phase 3 LOGICS trial evaluating RECORLEV for the treatment of endogenous Cushing’s syndrome. The study enrolled 44 patients to supplement the long-term...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that dosing has now been completed in all subjects enrolled in the Phase 1b multiple ascending dose (MAD) study of CRV431. The open-label MAD study was designed to assess...
Durect (NASDAQ:DRRX) reported data from its Phase 2a trial evaluating DUR-928 for the treatment of alcoholic hepatitis at the liver congress. The dose escalation trial evaluated doses of 30 mg, 90 mg, or 150 mg of DUR...
Applied Molecular Transport (NASDAQ:AMTI) initiated its Phase 2a trial evaluating AMT-101 for the treatment of ulcerative colitis. The trial will enrol some 100 patients with moderate-to-severely active ulcerative...
Hepion Pharmaceuticals (NASDAQ:HEPA) will present a poster on CRV431’s antifibrotic activity at the Digital International Liver Congress 2020, taking place from Aug. 27-29. Dr. Joseph Kuo will present a preclinical...
Outlook Therapeutics (NASDAQ:OTLK) reported topline results from its Phase 2 NORSE 1 trial evaluating ONS-5010 for the treatment of wet age-related macular degeneration (AMD). The study, whose primary endpoint is the...
Ovid Therapeutics (NASDAQ:OVID) reported positive topline results from its Phase 2 study evaluating soticlestat in children with Dravet syndrome or Lennox-Gastaut syndrome, two highly refractory epilepsy syndromes...
Imara’s (NASDAQ:IMRA) IMR-687 received European Commission orphan drug designation for the treatment of sickle cell disease. In a statement, Imara’s president and CEO, Rahul Ballal, said the designation reinforces “the...
Bristol Myers Squibb (NYSE:BMY) entered a definitive agreement to acquire closely-held Forbius, a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and...
CohBar (NASDAQ:CWBR) dosed first subjects with CB4211 in the Phase 1b stage of its Phase 1a/1b clinical trial for non-alcoholic steatohepatitis (NASH) and obesity. The Phase 1b study is designed to evaluate one dose...
Bionano Genomics (NASDAQ:BNGO) acquired closely-held Lineagen, a genetics diagnostic company, to further support its leadership in digital cytogenetics and comprehensive genetic diagnostics for pediatric...
Entera Bio (NASDAQ:ENTX) reported interim results from its Phase 2 trial assessing EB613 for the treatment of osteoporosis. The trial has currently enrolled 131 postmenopausal female subjects with osteoporosis, or low...
Precision BioSciences’ (NASDAQ:DTIL) allogeneic chimeric antigen receptor (CAR-T) cell therapy, PBCAR0191, received FDA fast track designation for the treatment of advanced B-cell precursor acute lymphoblastic leukemia...
Kazia Therapeutics’ (NASDAQ:KZIA) paxalisib received FDA fast track designation for the treatment of glioblastoma. Interim data from the company’s Phase 2 trial demonstrated overall survival of 17.7 months for patients...
Albireo Pharma (NASDAQ:ALBO) reported topline results from its Phase 2 trial evaluating elobixibat for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). The trial...
Vanda Pharmaceuticals (NASDAQ:VNDA) reported interim results from its Phase 3 trial assessing tradipitant for the treatment of COVID-19 pneumonia. The data are based on the first 60 patients enrolled in the study, who...
The FDA granted Mustang Bio’s (NASDAQ:MBIO) MB-107 rare pediatric disease designation for the treatment of X-linked severe combined immunodeficiency. Patients with X-linked severe combined immunodeficiency produce...
Imara (NASDAQ:IMRA) dosed the first patient in its Phase 2b Ardent trial evaluating IMR-687 for the treatment of sickle cell disease. The trial will enrol some 99 patients with sickle cell disease, who will receive...
Scholar Rock (NASDAQ:SRRK) received FDA rare pediatric disease designation for SRK-015 for the treatment of spinal muscular atrophy. Spinal muscular atrophy is a rare genetic disease that leads to motor function...
AzurRx BioPharma (NASDAQ:AZRX) reported positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients...
The FDA approved Lantheus’ (NASDAQ:LNTH) supplemental drug application for VIALMIXRFID, a device that activates the company’s DEFINITY injectable suspension. DEFINITY injectable suspension is an ultrasound imaging agent...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that the peer-reviewed journal, PLOS ONE, has published a paper highlighting the antiviral effects of CRV431. Co-authored by Hepion’s CSO, Dr. Daren Ure and CEO...